Joanne van Ryn

8.4k total citations · 2 hit papers
121 papers, 5.6k citations indexed

About

Joanne van Ryn is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Internal Medicine. According to data from OpenAlex, Joanne van Ryn has authored 121 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Cardiology and Cardiovascular Medicine, 31 papers in Hematology and 29 papers in Internal Medicine. Recurrent topics in Joanne van Ryn's work include Atrial Fibrillation Management and Outcomes (63 papers), Venous Thromboembolism Diagnosis and Management (29 papers) and Blood Coagulation and Thrombosis Mechanisms (24 papers). Joanne van Ryn is often cited by papers focused on Atrial Fibrillation Management and Outcomes (63 papers), Venous Thromboembolism Diagnosis and Management (29 papers) and Blood Coagulation and Thrombosis Mechanisms (24 papers). Joanne van Ryn collaborates with scholars based in Germany, United States and Netherlands. Joanne van Ryn's co-authors include Andreas Clemens, Joachim Stangier, Wolfgang Wienen, Martin Feuring, Sebastian Haertter, Karl‐Heinz Liesenfeld, M. Pairet, Tobias Litzenburger, J. Hirsh and Oliver Grottke and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.

In The Last Decade

Joanne van Ryn

116 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

2010 1.0k citations Joachim Stangier, Wolfgang Wienen et al. Thrombosis and Haemostasis profile →
A specific antidote for dabigatran: functional and structural characterization

2013 430 citations Joanne van Ryn, Herbert Nar et al. profile →

Peers

Countries citing papers authored by Joanne van Ryn

Since Specialization

Citations

This map shows the geographic impact of Joanne van Ryn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne van Ryn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne van Ryn more than expected).

Fields of papers citing papers by Joanne van Ryn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne van Ryn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne van Ryn. The network helps show where Joanne van Ryn may publish in the future.

Co-authorship network of co-authors of Joanne van Ryn

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne van Ryn. A scholar is included among the top collaborators of Joanne van Ryn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne van Ryn. Joanne van Ryn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate 2021 ·Journal of Thrombosis and Haemostasis ·(unknown), Ingrid Dijkgraaf, (unknown), Matthias Bauwens, Peter Leenders, Danyel Jennen, Marc R. Dweck, Jan Bucerius, Jacob J. Briedé, Joanne van Ryn, Vincent Brandenburg, Felix M. Mottaghy, Henri M.H. Spronk, Chris Reutelingsperger, Leon J. Schurgers	20
2	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding 2019 ·Circulation ·(unknown), Renato D. Lópes, James Aisenberg, Paul A. Reilly, Joanne van Ryn, Stephan Glund, Amelie Elsaesser, Frederikus A. Klok, Charles V. Pollack, Menno V. Huisman	29
3	Redistribution of dabigatran after idarucizumab administration in a 90-year old woman with renal failure due to persistent large intestinal bleeding 2019 ·Polskie Archiwum Medycyny Wewnętrznej ·Paulina Łopatowska, Elżbieta Młodawska, Bożena Sobkowicz, Joanne van Ryn, Anna Tomaszuk−Kazberuk	2
4	Thrombin promotes diet-induced obesity through fibrin-driven inflammation 2017 ·Journal of Clinical Investigation ·Anna K. Kopec, (unknown), Sherry Thornton, Joseph S. Palumbo, Eric S. Mullins, Senad Divanovic, Hartmut Weiler, A. Phillip Owens, Nigel Mackman, Ashley Goss, Joanne van Ryn, James P. Luyendyk, Matthew J. Flick	92
5	The discovery of dabigatran etexilate for the treatment of venous thrombosis 2016 ·Expert Opinion on Drug Discovery ·Martin Feuring, Joanne van Ryn	6
6	Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects 2016 ·The American Journal of Emergency Medicine ·Paul Reilly, Joanne van Ryn, Oliver Grottke, Stephan Glund, Joachim Stangier	22
7	Abstract 12901: Removal of Dabigatran Using Sorbent Hemadsorption 2015 ·Circulation ·George O. Angheloiu, Joanne van Ryn, Ashley Goss	2
8	The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders 2015 ·Journal of Thrombosis and Haemostasis ·Marc Jacquemin, Jaan Toelen, (unknown), (unknown), I. Vanlinthout, (unknown), Marijke Peetermans, Thomas Vanassche, Kathelijne Peerlinck, Joanne van Ryn, Peter Verhamme	35
9	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays 2014 ·Clinics in Laboratory Medicine ·Joanne van Ryn, Oliver Grottke, Henri M.H. Spronk	24
10	Dabigatran-induced anticoagulant and bleeding effects can be reversed with both prothrombin complex concentrates and a specific antidote (idarucizumab) in a lethal porcine polytrauma model 2014 ·European Heart Journal ·Oliver Grottke, Markus Honickel, Joanne van Ryn, Hugo Ten Cate, Henri M.H. Spronk, Rolf Rossaint	4
11	A SPECIFIC ANTIDOTE TO DABIGATRAN REDUCES BLOOD LOSS IN DABIGATRAN- AND TRAUMA-INDUCED BLEEDING IN PIGS 2014 ·Journal of the American College of Cardiology ·Oliver Grottke, Markus Honickel, Joanne van Ryn, Rolf Rossaint, Hugo Ten Cate, Henri M.H. Spronk	7
12	The Discovery of Dabigatran Etexilate 2013 ·Frontiers in Pharmacology ·Joanne van Ryn, Ashley Goss, Norbert Hauel, Wolfgang Wienen, Henning Priepke, Herbert Nar, Andreas Clemens	58
13	Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran 2012 ·The American Journal of Medicine ·Joanne van Ryn, Lawrence Baruch, Andreas Clemens	64
14	Fibrin formation by staphylothrombin facilitates Staphylococcus aureus-induced platelet aggregation 2012 ·Thrombosis and Haemostasis ·Thomas Vanassche, Alexandre Kauskot, Jan Verhaegen, Willy Peetermans, Joanne van Ryn, Olaf Schneewind, Marc Hoylaerts, Peter Verhamme	59
15	Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile 2012 ·European Journal of Clinical Pharmacology ·Andreas Clemens, Joanne van Ryn, Regina Sennewald, Norio Yamamura, Joachim Stangier, Martin Feuring, Sebastian Härtter	23
16	Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus adhesion to catheter and other foreign surfaces in vitro and abscess volume in vivo 2011 ·Journal of Thrombosis and Haemostasis ·Thomas Vanassche, Marijke Peetermans, Jan Verhaegen, Joanne van Ryn, Marc Hoylaerts, Peter Verhamme	2
17	Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence 2011 ·Journal of Thrombosis and Haemostasis ·Thomas Vanassche, Jan Verhaegen, Willy Peetermans, Joanne van Ryn, Alice G. Cheng, Olaf Schneewind, Marc Hoylaerts, Peter Verhamme	50
18	COX-2 Selectivity and Inflammatory Processes 2000 ·Current Medicinal Chemistry ·Joanne van Ryn, (unknown), M. Pairet	110
19	Clinical experience with cyclooxygenase-2 inhibitors 1999 ·Inflammation Research ·Joanne van Ryn, M. Pairet	31
20	Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer 1998 ·Inflammation Research ·M. Pairet, Joanne van Ryn, (unknown), (unknown), (unknown), G. Engelhardt	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact